男友太凶猛1v1高h,大地资源在线资源免费观看 ,人妻少妇精品视频二区,极度sm残忍bdsm变态

US warns of 'twindemic' prior to holiday season with COVID-19 pill, booster vaccines in clearance

Xinhua | Updated: 2021-10-12 09:07
Share
Share - WeChat

PILL AND BOOSTERS

Placards display signage for Johnson & Johnson and Pfizer COVID-19 vaccinations at a mobile COVID-19 vaccination center in the Brooklyn borough of New York, the United States, Aug 18, 2021. [Photo/Xinhua]

On Monday, drugmaker Merck asked the US Food and Drug Administration (FDA) to authorize its pill against COVID-19 in what would add an entirely new and easy-to-use weapon to the world's arsenal against the pandemic. If cleared by the agency, a decision that could come in a matter of weeks, it would be the first pill shown to treat COVID-19. All other FDA-backed treatments against the disease require an intravenous therapy (IV) or injection.

"An antiviral pill that people could take at home to reduce their symptoms and speed recovery could prove groundbreaking, easing the crushing caseload on US hospitals and helping to curb outbreaks in poorer countries with weak health care systems. It would also bolster the two-pronged approach to the pandemic: treatment, by way of medication, and prevention, primarily through vaccinations," reported national broadcaster NBC.

Merck and its partner Ridgeback Biotherapeutics said they specifically asked the agency to grant emergency use for adults with mild-to-moderate COVID-19 who are at risk for severe disease or hospitalization. Merck expects to be able to produce enough pills for 10 million people by the end of this year. The pill is meant to be taken at home as four capsules twice a day for five days, for a total of 40 pills.

Meanwhile, the US federal government is expected to take a significant step this week toward offering booster doses to a much wider range of Americans as advisers to the FDA meet on Thursday and Friday to discuss recipients of the Johnson & Johnson and Moderna coronavirus vaccines. So far, regulators have authorized booster shots only for certain adults who received the Pfizer-BioNTech vaccine.

"The (US President Joe) Biden administration is eager to shore up the protection provided by all three (officially authorized) vaccines. And federal officials have become increasingly worried in particular about the more than 15 million Americans who received the Johnson & Johnson vaccine, which is less effective than the others," reported The New York Times on Monday.

On Thursday, the FDA advisory panel of vaccine experts will discuss safety and efficacy data regarding booster shots for Moderna recipients. On Friday, the group will discuss Johnson & Johnson boosters. The agency typically issues decisions within a few days of advisory committee meetings. The expert committee will also hear a presentation on Friday from scientists on the effectiveness of mixing different brands of vaccines.

|<< Previous 1 2 3   
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
主站蜘蛛池模板: 凤庆县| 辰溪县| 和平县| 虎林市| 缙云县| 思南县| 新乐市| 楚雄市| 民乐县| 曲靖市| 田阳县| 西宁市| 盐源县| 峨山| 吐鲁番市| 东港市| 晋宁县| 宜丰县| 怀集县| 苏州市| 家居| 如皋市| 武汉市| 五莲县| 澳门| 泉州市| 吉水县| 黔南| 大关县| 饶平县| 金华市| 土默特左旗| 莆田市| 友谊县| 云林县| 景洪市| 凌海市| 汕头市| 伊金霍洛旗| 宁南县| 搜索|